MGteam

Is there an update on Vyvgart approval for seronegative MG patients?

Great news! A phase 3 study showed that efgartigimod (Vyvgart) led to statistically significant and clinically meaningful improvements in daily function for people with seronegative MG. This included all three major subtypes: MuSK-positive, LRP4-positive Show Full Answer

Is there an update on Vyvgart approval for seronegative MG patients?

Great news! A phase 3 study showed that efgartigimod (Vyvgart) led to statistically significant and clinically meaningful improvements in daily function for people with seronegative MG. This included all three major subtypes: MuSK-positive, LRP4-positive, and triple seronegative.

The study involved 119 participants and found that Vyvgart was well tolerated, with no new safety issues. The most common side effects included:

- Respiratory tract infection
- Headache
- Urinary tract infection

Based on these positive results, the drugmaker Argenx plans to submit an application to the FDA by the end of 2025 to expand approval so more people with seronegative MG can access the treatment.

If approved, Vyvgart could become the only FcRn blocker with such a broad label, filling an important treatment gap for people with anti-LRP4 antibodies or those who are triple seronegative—two groups that currently have no FDA-approved treatments specifically for them.

This is particularly meaningful since treatment advances have mainly focused on AChR- or MuSK-positive patients until recently.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Vyvgart Improves Daily Function for Seronegative MG in Phase 3 Trial